June 12 – 17, 2022
Vaccines for known and emerging diseases as well as new therapeutic applications of viruses will require multiple doses and high virus input per dose or treatment. Therefore, there is a clear need for innovation in vaccine manufacturing. Yet, process optimization and intensification are cost- and labor-intensive challenges and thus not always considered as economically reasonable. To tackle this problem and compete against outdated cost calculations, this work aims to transfer knowledge and techniques that were acquired within a decade of protein production process development into the field of viral vaccine manufacturing. This comprises the development of monoclonal suspension MDCK cell lines using an automated single-cell cloning strategy in chemically defined medium. Subsequently, a scale-down into the fully automated single-use Ambr®15 microbioreactor system (Sartorius, Germany) was established for influenza A virus (IAV) production. This may help to accelerate process development and optimization by parallelized screening of multiple parameters in a high-throughput manner.
Please click Download on the upper right corner to see the full abstract.
Tilia Zinnecker, Ilona Behrendt, Maverick Lau, Angelika Hinkelmann, Kristin Thiele, Najd Badri, Diogo Araujo, Yvonne Genzel, and Udo Reichl, "Automated single-cell cloning in chemically defined medium for new suspension MDCK cell lines and scale-down of influenza A virus production into ambr®15 microbioreactors" in "Vaccine Technology VIII", Tarit Mukhopadhyay, Merck Research Laboratories, USA; Charles Lutsch, Sanofi Pasteur, France; Linda Hwee-Lin Lua, University of Queensland, Australia; Francesc Godia, Universitat Autònoma de Barcelona, Spain Eds, ECI Symposium Series, (2022). https://dc.engconfintl.org/vaccine_viii/55